CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01316458
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:33.012320+00:00
Published At: 2017-06-01T00:00:00+00:00
Record Updated At: 2017-06-01
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Prostatic Neoplasm", "Genital Neoplasms, Male", "Neoplasms, Abdominal", "Urogenital Neoplasms", "Genital Diseases, Male", "Prostatic Diseases", "Antineoplastic Agents", "Imatinib"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2017-06-01"
protocolSection.identificationModule.nctId: "NCT01316458"
protocolSection.identificationModule.officialTitle: "An Open-label, Multicenter, Phase II Study to Evaluate the Ability of Glivec\u00ae (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response in Patients With Rising PSA Following Radical Prostatectomy"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.